NCT00821249 - A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

March 16, 2016

Study Completion Date

March 16, 2016

Conditions

Multiple MyelomaPlasma Cell Leukemia

Interventions

DRUG

ARRY-520, KSP(Eg5) inhibitor; intravenous

Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.

DRUG

Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Part 1: standard of care; Part 2: standard of care; Part 3: standard of care.

DRUG

Dexamethasone, steroid; oral

Part 3: standard of care.

Trial Locations (5)

Fox Chase Cancer Center, Philadelphia

Emory University, Winship Cancer Institute, Atlanta

Karmanos Cancer Institute, Detroit

MD Anderson Cancer Center, Houston

Fred Hutchinson Cancer Research Center, Seattle